Nebivololo Krka

Nebivolol, the active ingredient in Nebivololo Krka, is a β1‑selective beta‑blocker presented as a tablet for oral use. It lowers elevated blood pressure, improves cardiac output, and provides heart‑rate control in adults with hypertension or chronic heart failure, offering additional vasodilatory benefits through nitric‑oxide release.

GNH USA supplies Nebivololo Krka as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring reliable quality and regulatory compliance.

Nebivolol is prescribed for cardiovascular disorders that involve high blood pressure or reduced heart function.

Hypertension: consistently lowers both systolic and diastolic blood pressure, helping to achieve target values and reducing the long‑term risk of stroke, myocardial infarction, and renal complications. Heart failure: improves left‑ventricular ejection fraction and reduces symptomatic fatigue, thereby decreasing hospital admissions and mortality in patients with chronic systolic heart failure. Post‑myocardial infarction: may aid in secondary prevention by controlling blood pressure and heart rate.

Nebivolol may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Fatigue - Dizziness or light‑headedness - Headache - Bradycardia - Nausea

Serious or Rare Side Effects: - Severe bradycardia or heart block - Marked hypotension - Bronchospasm in patients with asthma or COPD - Allergic reactions such as rash, angioedema, or anaphylaxis

Before initiating Nebivololo Krka, clinicians should consider several safety aspects to minimise risk.

Cardiovascular assessment: evaluate baseline heart rate, blood pressure, and cardiac function. Renal or hepatic impairment: adjust dosing or monitor closely in patients with reduced organ function. Respiratory disease: use caution in asthma or chronic obstructive pulmonary disease due to possible bronchospasm. Pregnancy and lactation: avoid unless benefits outweigh potential risks, as safety data are limited. Concomitant beta‑blockers: do not combine with other β‑blockers without specialist supervision. Discontinuation: taper gradually to prevent rebound hypertension or tachycardia. Store at ambient temperature: keep below 25 °C in the original packaging, protected from moisture and light.

Nebivolol can interact with several medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Non‑selective beta‑blockers: additive β‑blockade may cause excessive bradycardia or hypotension. - Calcium‑channel blockers (verapamil, diltiazem): increase nebivolol levels and risk of heart block. - Clonidine: concurrent use may precipitate severe hypertension on abrupt withdrawal.

Moderate Interactions (Monitor Closely): - ACE inhibitors or ARBs: monitor for additive blood‑pressure lowering. - Diuretics: watch for electrolyte imbalance and excessive hypotension. - Antidiabetic agents: nebivolol may mask hypoglycaemia symptoms.